Leukemia Therapeutics Market

Executive Summary

Leukemia Therapeutics Market was valued at US $3.41 billion in 2021 and is projected to grow at 5.10% CAGR over the forecast period to reach US $4.59 billion by 2027. Leukemia Therapeutics Market represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.18 billion opportunity in 2027 over 2021.

Leukemia Therapeutics from Consainsights analyses the Leukemia Therapeutics Market in the Life Sciences industry over the forecast period to 2027.

Leukemia Therapeutics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Leukemia Therapeutics segmentation includes Type of Leukemia, Treatment Type, Molecule Type, Mode of Administration, Gender, Region and Geography.

Based on the Type of Leukemia, the Leukemia Therapeutics analysis covers Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia.

In Type of Leukemia segment, Chronic Myeloid Leukemia segment has highest cagr growth of 4.52%.

Based on the Treatment Type, the Leukemia Therapeutics analysis covers Targeted Drugs & Immunotherapy, Chemotherapy.

In Treatment Type segment, Targeted Drugs & Immunotherapy segment has highest cagr growth of 4.52%.

Based on the Molecule Type, the Leukemia Therapeutics analysis covers Small Molecules, Biologics.

In Molecule Type segment, Small Molecules segment has highest cagr growth of 4.52%.

Based on the Mode of Administration, the Leukemia Therapeutics analysis covers Oral Mode, Injectable Mode.

In Mode of Administration segment, Oral Mode segment has highest cagr growth of 4.52%.

Based on the Gender, the Leukemia Therapeutics analysis covers Males, Females.

In Gender segment, Males segment has highest cagr growth of 4.52%.

Based on the Region, the Leukemia Therapeutics analysis covers North America, Europe, Asia Pacific, Rest of the World.

In Region segment, North America segment has highest cagr growth of 4.52%.

Based on the region, the Leukemia Therapeutics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Novartis AG, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Sanofi, Pfizer, Amgen, Gilead Sciences, Takeda, Celgene and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type of Leukemia

Introduction

In 2021, Chronic Myeloid Leukemia segment has the highest revenue of US $1.61 billion and is expected to grow at CAGR of 4.52% by 2027 Chronic Myeloid Leukemia segment has highest cagr growth of 4.52%.

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia segment was valued at US $1.46 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $2.17 billion by 2027. Chronic Myeloid Leukemia segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.56 billion opportunity in 2027 over 2021.

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia segment was valued at US $0.92 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $1.37 billion by 2027. Chronic Lymphocytic Leukemia segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.35 billion opportunity in 2027 over 2021.

Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia segment was valued at US $0.32 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $0.47 billion by 2027. Acute Lymphocytic Leukemia segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.12 billion opportunity in 2027 over 2021.

Acute Myeloid Leukemia

Acute Myeloid Leukemia segment was valued at US $0.39 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $0.58 billion by 2027. Acute Myeloid Leukemia segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.15 billion opportunity in 2027 over 2021.

Treatment Type

Introduction

In 2021, Targeted Drugs & Immunotherapy segment has the highest revenue of US $1.92 billion and is expected to grow at CAGR of 4.52% by 2027 Targeted Drugs & Immunotherapy segment has highest cagr growth of 4.52%.

Targeted Drugs & Immunotherapy

Targeted Drugs & Immunotherapy segment was valued at US $1.74 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $2.58 billion by 2027. Targeted Drugs & Immunotherapy segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.67 billion opportunity in 2027 over 2021.

Chemotherapy

Chemotherapy segment was valued at US $1.35 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $2.00 billion by 2027. Chemotherapy segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.52 billion opportunity in 2027 over 2021.

Molecule Type

Introduction

In 2021, Small Molecules segment has the highest revenue of US $2.34 billion and is expected to grow at CAGR of 4.52% by 2027 Small Molecules segment has highest cagr growth of 4.52%.

Small Molecules

Small Molecules segment was valued at US $2.12 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $3.15 billion by 2027. Small Molecules segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.81 billion opportunity in 2027 over 2021.

Biologics

Biologics segment was valued at US $0.97 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $1.44 billion by 2027. Biologics segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.37 billion opportunity in 2027 over 2021.

Mode of Administration

Introduction

In 2021, Oral Mode segment has the highest revenue of US $2.30 billion and is expected to grow at CAGR of 4.52% by 2027 Oral Mode segment has highest cagr growth of 4.52%.

Oral Mode

Oral Mode segment was valued at US $2.08 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $3.10 billion by 2027. Oral Mode segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.80 billion opportunity in 2027 over 2021.

Injectable Mode

Injectable Mode segment was valued at US $1.00 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $1.49 billion by 2027. Injectable Mode segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.38 billion opportunity in 2027 over 2021.

Gender

Introduction

In 2021, Males segment has the highest revenue of US $3.15 billion and is expected to grow at CAGR of 4.52% by 2027 Males segment has highest cagr growth of 4.52%.

Males

Males segment was valued at US $2.85 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $4.25 billion by 2027. Males segment represented US $0.30 billion opportunity over 2019-2021 and estimated to create US $1.10 billion opportunity in 2027 over 2021.

Females

Females segment was valued at US $0.23 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $0.34 billion by 2027. Females segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.09 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $1.53 billion and is expected to grow at CAGR of 4.52% by 2027 North America segment has highest cagr growth of 4.52%.

North America

North America segment was valued at US $1.39 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $2.07 billion by 2027. North America segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.53 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $0.78 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $1.16 billion by 2027. Europe segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.30 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $0.67 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $0.99 billion by 2027. Asia Pacific segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.26 billion opportunity in 2027 over 2021.

Rest of the World

Rest of the World segment was valued at US $0.25 billion in 2019 and is projected to grow at 4.52% CAGR over the forecast period to reach US $0.38 billion by 2027. Rest of the World segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.